Skip to main content
. 2017 Oct;6(5):894–898. doi: 10.21037/tau.2017.07.27

Table 1. Patient demographics.

Demographics N=51
Mean age [range] in years 54.5 [27–67]
Race
   Caucasian 49 (96%)
   African-American 2 (4%)
   Asian 0 (0%)
   Other 0 (0%)
Relationship status
   In a relationship 40 (78%)
   Single 11 (22%)
Comorbidities
   Diabetes mellitus 10 (19%)
   Hypertension 27 (53%)
   CAD/PVD 4 (7%)
Duration of Peyronie’s disease (mean, range) in months 25.5 [1–120]
Pain
   No 28 (55%)
   Yes 23 (45%)
Previous treatment for Peyronie’s disease
   No 29 (57%)
   Oral 17 (33%)
   Injectable 5 (10%)
History of trauma
   No 33 (65%)
   Yes 18 (35%)
Treatment for erectile dysfunction
   No 22 (43%)
   PDE-5 Inhibitors 27 (53%)
   VED 2 (4%)
Direction of curvature
   Dorsal 27 (53%)
   Dorsal-lateral 13 (25%)
   Lateral 11 (22%)
Degree of curvature
   30˚–60˚ 26 (51%)
   >60˚ 25 (49%)
Vascular findings
   Venous leak 30 (59%)
   Arterial insufficiency 1 (2%)
   Mixed vascular 6 (12%)
   Non-vascular 14 (27%)
Mean follow-up [range] in months 9.4 [3–26]

CAD, coronary artery disease; PVD, peripheral vascular disease; VED, vacuum erection device.